MOTS-C and NAD+ are often grouped together in longevity conversations, but biologically they are very different. One is a mitochondrial-derived signalling peptide, the other is a coenzyme central to how every cell produces energy. Comparing them is less about asking which is stronger and more about understanding what each pathway actually does, and how much of that is actually proven in humans.
MOTS-C is encoded directly by mitochondrial DNA and activates AMPK. Human observational research is genuinely substantial, but no completed human trial of administered MOTS-C exists yet.
NAD+ biology has substantially more human research through precursors like NR and NMN. Multiple controlled trials confirm these reliably raise NAD+ levels, but clinical outcome benefits remain inconsistent and indication-specific.
So which is better? If you are weighing strength of human evidence, NAD+ biology is better studied. If you are weighing novelty of mechanism, MOTS-C is a genuinely interesting emerging area, but still investigational. Neither should be presented as a proven energy, longevity, or anti-ageing treatment.
If you have come across MOTS-C and NAD+ in the same conversation, it is usually because both get discussed under the broad mitochondrial health and longevity umbrella. But one is a peptide, and one is not.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme, not a peptide. It is a molecule your cells use directly in energy metabolism, DNA repair, and many other processes. MOTS-C is a mitochondrial-derived peptide, a small protein signal, encoded by mitochondrial DNA itself. They are not two versions of the same treatment, and they do not work through the same mechanism.
Use the tabs to focus on one pathway at a time. Both pathways and their evidence caveats are shown in full below regardless of which tab is active.
Mitochondrial-derived signalling peptide
Coenzyme raised by NR and NMN precursors
MOTS-C is a mitochondrial signalling peptide that activates AMPK, a central cellular energy-sensing pathway. Human observational research is substantial. Human interventional trial data for administered MOTS-C does not yet exist.
MOTS-C is unusual among peptides because it is encoded by mitochondrial DNA rather than nuclear DNA, making it a direct product of the mitochondria themselves. The original mechanism research (published in Cell Metabolism) established that MOTS-C promotes metabolic homeostasis and reduces obesity and insulin resistance in mice, working through AMPK activation.
Separately, there is a genuinely substantial body of human observational research, studies that measure a person's own naturally occurring MOTS-C levels rather than administering it as a treatment. These consistently show circulating MOTS-C declines with age, rises measurably after exercise, and correlates with muscle strength and lean mass in healthy adults. One study found MOTS-C levels were lower in COPD patients and associated with poorer exercise capacity. This is real, human, peer-reviewed data, it is just observational, not interventional.
What does not exist yet is a completed human trial testing whether giving someone MOTS-C produces a therapeutic benefit. A Phase 2a trial evaluating subcutaneous MOTS-C for insulin sensitivity in adults with prediabetes and overweight or obesity is currently recruiting (registered on ClinicalTrials.gov), but no results have been published.
NAD+ is a coenzyme required for cellular energy production. Its precursors reliably raise NAD+ levels in humans, but whether that translates into measurable benefits is far less settled.
NAD+ declines with age, and restoring it has shown real benefits in animal longevity studies. Much of the human supplementation research has focused on NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which the body converts into NAD+.
Here is what is genuinely well established: a head-to-head human trial (Christen et al., published in Nature Metabolism, 2026) confirmed both NR and NMN reliably raise circulating NAD+, roughly doubling levels within 14 days. Other controlled trials have shown similar increases, in some cases 2.6 to 3 times baseline NAD+ within 5 to 10 weeks.
What is much less consistent is what that increase actually does for you. A randomised controlled trial in long-COVID patients (published in eClinicalMedicine, part of The Lancet Group) found NR raised NAD+ effectively but showed no significant difference from placebo on cognition, sleep, fatigue, or mood in the primary analysis. A 2025 systematic review and meta-analysis of 10 randomised controlled trials (437 patients) found no significant pooled benefit for muscle mass, strength, or physical function in older adults. A separate meta-analysis of NMN's effects on glucose and lipid metabolism found the same pattern, NAD+ levels rose reliably, but most clinically relevant outcomes did not differ significantly from control.
This is the honest, consistent finding across the current human evidence: raising NAD+ is a reliable, measurable biochemical effect. Clinical outcome benefits across human trials remain inconsistent and indication-specific. Improvements in energy, cognition or longevity have not been consistently demonstrated.
Research moves along a continuum. It matters where each of these sits, and it matters that moving further along the pathway does not automatically establish a proven clinical benefit.
These are observational associations from measuring people's own natural MOTS-C. They do not demonstrate that administering MOTS-C as a treatment produces those outcomes. No completed human interventional trial has established that yet.
“MOTS-C is proven to build new mitochondria in humans.”
Not establishedNot yet, at least not through direct testing. There is substantial human observational data showing natural MOTS-C levels correlate with age, exercise, and muscle strength, but no completed trial has tested whether administering MOTS-C to people produces that effect. The therapeutic mechanism research remains dominated by animal and cell studies.
“If NAD+ levels go up, you will feel more energetic.”
Not necessarilyNot necessarily. Raising NAD+ is well proven. Multiple controlled trials have failed to find a significant difference from placebo on fatigue, cognition, or physical performance, even when NAD+ levels clearly rose.
“NR and NMN are basically the same thing.”
Not the sameThey are both NAD+ precursors, but they are absorbed and metabolised differently, and a 2026 head-to-head human trial found real differences in how effectively each raises NAD+ and its downstream effects on gut bacteria and short-chain fatty acid production.
“One of these is definitively the better choice.”
No single winnerNo. They are not interchangeable options for the same goal. MOTS-C research is exploring metabolic and mitochondrial signalling specifically. NAD+ research is broader but has struggled to show consistent outcome benefits despite reliably changing the underlying biochemistry.
If someone asked which of these is worth it, I would want to know what they actually mean by that. If they mean will this measurably improve how I feel, the honest answer for both is that the human evidence is not there yet, for MOTS-C because the human trials have not happened, for NAD+ precursors because the trials that have happened mostly have not found the benefit people expect. That is not the same as saying neither is interesting or worth discussing in the right clinical context, it is saying the marketing language around both has outpaced what has actually been shown in people. If you are weighing them up, it is also worth understanding whether injectable peptides are safe and where the real risks actually sit.
No. MOTS-C is a mitochondrial-derived peptide. NAD+ is a coenzyme. They are structurally and functionally different, though both are involved in mitochondrial and energy-related research.
If you would like to understand whether peptide therapy may be relevant to your goals, you can explore the Peptide Therapy Hub or book a consultation. Nothing is recommended without a proper assessment.
If a peptide is not the right route for you, I will tell you honestly.